Application by Teva for what is referred to as an Arrow declaration, that its proposed acts of importing and selling generic fingolimod to treat relapsing-remitting multiple sclerosis (RRMS) at a daily dose of 0.5 mg p.o. was obvious at the priority date of European Patent EP 2 959 894 (EP 894), for which Novartis AG is the registered proprietor.
Judges:
Mrs Justice Bacon
Citations:
[2022] EWHC 2779 (Ch)
Links:
Jurisdiction:
England and Wales
Intellectual Property
Updated: 14 November 2022; Ref: scu.682732